Somaxon announces senior commercial leadership appointments
This article was originally published in Scrip
Somaxon Pharmaceuticals (US) has appointed Daniel Schneider to the newly-created position of vice-president of sales and Joseph Merkert to the newly-created position of vice-president of sales operations and managed care. Mr Schneider has more than 16 years' experience in pharmaceutical sales and sales management, the last 10 of which were spent at Sepracor, most recently serving as area vice-president of sales. Mr Merkert joins from Verus Pharmaceuticals, where he was vice-president of commercial operations.
You may also be interested in...
The efforts to upgrade FDA’s information technology infrastructure may be opening up into an opportunity to reinvent its processes for regulatory decision making.
FDA should have all coronavirus vaccines evaluated by Vaccines and Related Biological Products Advisory Committee before approval, Democratic senators and representatives say; House subcommittee also wants FDA to require 30,000 participants in Phase III trials.
Biocon’s itolizumab gets clearance in India for restricted emergency use in COVID-19 patients, amid some concerns around small study numbers. But company says data are compelling and cites compassionate use substantiation, while partner Equillium expects to pursue a global study under US IND.